New Medicine - A Comprehensive Information and Consulting Service  
HOME PRODUCTS & SERVICES ORDER/INQUIRY PRESS RELEASES EMPLOYMENT CONTACT US

FUTURE ONCOLOGY
Volume 6 #3/4 December 31, 2000


Technology Update

SYNTHETIC NUCLEIC ACID SEQUENCE CONSTRUCTS AS ONCOLOGY THERAPEUTICS-PART III

Molecular Targets in Oncology

  • C-myc
    • Oncomyc-NG (AVI-4126)
    • INX-3280
  • C-myb
    • INX-3001
  • Raf
    • ISIS 5132
    • LE-AON
  • Ras
    • ISIS 2503
  • Protein Kinases
    • ISIS 3521
    • GEM 231
  • Bcl-2
    • Genasense (G3139)
  • Vascular Endothelial Growth Factor (VEGF)
    • Angiozyme
  • DNA-MeTase (DNA Methyltransferase)
    • MG98
  • Ribonucleotide reductase (RNR)
    • GTI 2040
  • Insulin-like Growth Factor (IGF)-I -II and IGF-Ir

Other Potential SNAS Interventions in Oncology

  • Oncogene Inhibition
    • Oncogene bcr-abl
    • Murine double-minute 2 (mdm2)
  • Modulation of Tumor Suppressor Genes
    • BRCA1
  • Modulation of Signal Tranduction Pathways
    • Epidermal growth factor (EGF) and transforming growth factor (TGF)-α
  • Prevention of Metastasis
    • The α V integrins
    • Focal adhesion kinase
  • Enhancement of Apoptosis
    • Inhibitors of apoptosis proteins (IAP)
  • Telomerase Inhibition
  • Modulation of Chemotherapeutics
  • Immunotherapy
  • Viral Inhibition

Diagnostic, Research, and Drug Discovery Applications

Developers of SNAS-Related Pharmaceuticals

  • atugen
  • AVI BioPharma
  • Coley Pharmaceutical Group
  • Cytoclonal Pharmaceutics
  • EpiGenesis Pharmaceuticals
  • Gemini Technologies
  • Genta
  • Hybridon
  • Immusol
  • Inex Pharmaceuticals
  • Isis Pharmaceuticals
  • Lorus Therapeutics
  • MethylGene
  • Ribozyme Pharmaceuticals (RPI)

HOME | PRODUCTS & SERVICES | ORDER/INQUIRY | PRESS RELEASES | EMPLOYMENT | CONTACT US

NEW MEDICINE, INC.
PHONE: 949-830-0448   FAX: 949-830-0887